Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases
- PMID: 6141712
Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases
Abstract
In parkinsonian brain, TH and the BP cofactor, as well as DBH and PNMT with phenylethanolamine as substrate, are decreased. However, decrease in AADC with L-DOPA as substrate was not statistically significant. TH activity has also been shown to be decreased in striatonigral degeneration and Shy-Drager syndrome. TH reduction only in striatum but not in substantia nigra was found in a case of juvenile Parkinson's disease. Changes in AADC with L-DOPA or L-5-HTP as substrates varied in parkinsonian brains. PNMT with norepinephrine as substrate was also significantly decreased in parkinsonian brains. After administration of tyrosine to mice, the BP concentration was increased in striatum, adrenals, and serum. Mean BP concentration in serum of parkinsonian patients was slightly but significantly lower than that in controls. The serum BP increased three- to sevenfold in response to an oral tyrosine load in controls, whereas there was no increase or only a minor one (less than threefold) in parkinsonian patients. Our present results indicate that all catecholamine-synthesizing enzymes and BP synthesis may be impaired in Parkinson's disease.
Similar articles
-
Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.Clin Chim Acta. 1977 Mar 1;75(2):221-32. doi: 10.1016/0009-8981(77)90193-0. Clin Chim Acta. 1977. PMID: 14798
-
[Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].Tanpakushitsu Kakusan Koso. 1981 Aug;26(11):1781-8. Tanpakushitsu Kakusan Koso. 1981. PMID: 6117927 Review. Japanese. No abstract available.
-
Biochemical aspects of Parkinson's disease.Adv Neurol. 1993;60:165-74. Adv Neurol. 1993. PMID: 8093575 Review. No abstract available.
-
Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.J Neural Transm Suppl. 2007;(72):113-20. doi: 10.1007/978-3-211-73574-9_14. J Neural Transm Suppl. 2007. PMID: 17982884 Review.
-
[Expression and assessment of double genes of tyrosine hydroxylase gene and aromatic L-amino acid decarboxylase gene in vitro].Sheng Li Xue Bao. 2003 Oct 25;55(5):583-8. Sheng Li Xue Bao. 2003. PMID: 14566408 Chinese.
Cited by
-
Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase.Int J Mol Sci. 2022 Apr 10;23(8):4176. doi: 10.3390/ijms23084176. Int J Mol Sci. 2022. PMID: 35456994 Free PMC article. Review.
-
Dopamine Synthesis as a Mechanism of Brain Plasticity in Nigrostriatal System Pathology.Dokl Biochem Biophys. 2018 Mar;479(1):83-86. doi: 10.1134/S1607672918020096. Epub 2018 May 19. Dokl Biochem Biophys. 2018. PMID: 29779103
-
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.J Neurosci. 1998 Jun 1;18(11):4271-84. doi: 10.1523/JNEUROSCI.18-11-04271.1998. J Neurosci. 1998. PMID: 9592104 Free PMC article.
-
Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease.Brain Pathol. 2007 Jan;17(1):24-30. doi: 10.1111/j.1750-3639.2006.00032.x. Brain Pathol. 2007. PMID: 17493034 Free PMC article.
-
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.Pharmaceuticals (Basel). 2012 Jun 4;5(6):553-90. doi: 10.3390/ph5060553. Pharmaceuticals (Basel). 2012. PMID: 24281662 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous